

**Supplementary table1. Pharmacological treatment post PFO closure**

Baseline anti-thrombotic treatment immediately post PFO closure	
- Aspirin + clopidogrel	58/59 (98.3%)
- Clopidogrel + OAC	1/59 (1.7%)
Switch to OAC or DOAC after diagnosis of supraventricular arrhythmia	10/18 (55.6%)
Anti-thrombotic treatment at last clinical follow-up	
- Aspirin	27/59 (45.76%)
- Clopidogrel	20/59 (33.91%)
- Aspirin + clopidogrel	5/59 (8.47%)
- DOAC	5/59 (8.47%)
- OAC	0/59 (0%)
- None	2/59 (3.39%)
Baseline anti-arrhythmic treatment immediately post PFO closure	
- Betablockers	8/59 (13.56%)
- Amiodarone	1/59 (1.69%)
- None	50/59 (84.75%)
Start (or switch) of anti-arrhythmic treatment during follow-up	
- Patients with supraventricular arrhythmia post PFO closure	6/18 (33.3%)
- Patients without supraventricular arrhythmia post PFO closure	1/41 (2.44%)
New anti-arrhythmic drug introduced during follow-up	
- Betablockers	2/7 (28.57%)
- Sotalol	4/7 (57.14%)
- Amiodarone	1/7 (14.29%)
Values are n (%). PFO: patent foramen ovale DOAC: direct anticoagulants OAC: oral anticoagulation	